Uses of biologics in allergic diseases

Treatment options for respiratory and dermatologic diseases have expanded considerably during the past 10 years, improving the quality of life of many people with chronic, debilitating, poorly controlled allergic conditions. Some of the most promising are biologic therapies, targeting IgE, interleukin (IL)-5, IL-4, and IL-13. With new monoclonal antibodies being developed and approved at a rapid pace, choosing the best agent for each clinical situation can be a formidable task. This review focuses on monoclonal antibodies for asthma, nasal polyps, urticaria, and atopic dermatitis that are approved by the US Food and Drug Administration (FDA) for each condition or have been examined in phase 2 or 3 clinical trials with favorable results.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: CME Review Source Type: research